Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Director departure
Quarterly results
GENTA INC DE (GNTA) Create: Alert

All | News | Filings
Date FiledTypeDescription
06/18/2012 GN Genta Announces Agreement With FDA on Special Protocol Assessment of Phase 3 Trial of Tesetaxel as Initial Chemotherapy for Women With Metastatic Breast Cancer
06/18/2012 GN Genta Incorporated to Present at 2012 BIO International
05/31/2012 GN Genta Initiates Randomized Trial of Tesetaxel as First-Line Therapy for Women With Recurrent Breast Cancer
05/22/2012 GN Tesetaxel Results as Initial Chemotherapy for Women With Recurrent Breast Cancer to be Highlighted at ASCO
05/14/2012 GN Genta Incorporated Reports First Quarter 2012 Financial Results
05/08/2012 GN Genta Initiates Randomized Trial of Tesetaxel in Gastric Cancer
04/24/2012 GN Genta Appoints Dr. Brian Leyland-Jones and Richard J. Moran to Its Board of Directors
02/06/2012 GN Genta Incorporated to Present at 14th Annual BIO CEO ' Investor Conference
01/19/2012 GN New Clinical Trial Confirms the Activity of Tesetaxel in Patients With Advanced Gastric Cancer
01/03/2012 GN Genta Incorporated to Present at the 5th Annual OneMedForum in San Francisco
12/08/2011 GN Genta Announces Results From Clinical Trial of Tesetaxel as Initial Chemotherapy for Women With Recurrent Breast Cancer
11/10/2011 GN Genta Incorporated Reports Third Quarter 2011 Financial Results and Recent Corporate Highlights
11/03/2011 GN Genta Incorporated to Host Conference Call to Discuss Third Quarter 2011 Highlights and Financial Results
09/08/2011 GN Genta Incorporated to Present at the Rodman ' Renshaw Annual Global Investment Conference
09/06/2011 GN Genta Completes Financing of Up to $12.7 Million
06/29/2011 GN Genta Updates Tesetaxel Clinical Trials Progress at the BIO International Business Forum
06/23/2011 GN Genta Incorporated to Present at the 2011 BIO International Business Forum
06/08/2011 GN Tesetaxel Results From Multiple Dose-Ranging Clinical Trials Updated at ASCO
05/23/2011 GN Phase 3 Trial of Genasense(R) in Advanced Melanoma Does Not Show Significant Increase in Overall Survival
05/17/2011 GN Genta Announces Clinical Presentations on Lead Compounds, Tesetaxel and Genasense(R), at 2011 Annual ASCO Meeting
05/16/2011 GN Genta Incorporated Reports First Quarter 2011 Corporate Highlights and Financial Results
05/09/2011 GN Genta Incorporated to Host Conference Call to Discuss First Quarter 2011 Highlights and Financial Results
05/03/2011 GN Genta Initiates Front-Line Combination Trial of Tesetaxel in Patients With Advanced Gastric Cancer
04/26/2011 GN Genta Initiates Tesetaxel Clinical Trial in Japan to Kickoff Comprehensive Development Program in East Asia
04/21/2011 GN Genta Updates Guidance on Survival Results From Phase 3 AGENDA Trial of Genasense(R) in Advanced Melanoma
03/30/2011 GN Genta Incorporated Reports Fourth Quarter and 2010 Year-End Financial Results and Updates Key Product and Corporate Developments
03/24/2011 GN Genta Incorporated to Host Conference Call to Discuss Fourth Quarter 2010 Highlights and Financial Results (Webcast)
03/21/2011 GN Stock Symbol for Genta Incorporated Reverts to GNTA.OB
02/17/2011 GN Board of Directors of Genta Incorporated Announces Reverse Split of Company's Common Stock
02/10/2011 GN Genta Initiates Trial With Tesetaxel as First- and Second-Line Chemotherapy for Patients With Advanced Prostate Cancer
02/07/2011 GN Genta Incorporated to Present at the 13th Annual BIO CEO ' Investor Conference

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy